Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibodies

This page shows the latest monoclonal antibodies news and features for those working in and with pharma, biotech and healthcare.

Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

bacterium. Overall, Gates MRI says it intends to identify “novel candidates for drugs, vaccines, monoclonal antibodies, and diagnostics”across all three of its target disease areas.

Latest news

More from news
Approximately 2 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • The tipping point The tipping point

    For example, since 2015, when the first monoclonal antibody biosimilar, infliximab, was launched in Europe we have seen a notable increase in the overall use of infliximab. ... For example, providing therapeutic drug monitoring (TDM) to minimise loss of

  • What makes the difference in the biosimilar battle? What makes the difference in the biosimilar battle?

    Taking the example of multiple blockbuster monoclonal antibodies close to their patent expiry dates, we can see that numerous big pharma companies like Merck, Amgen and Pfizer and even smaller to

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... The other two companies, the Swedish company, BioInvent, and the British company, Abzena, have

  • Deal Watch April 2016 Deal Watch April 2016

    1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and

  • V Bryan Lawlis joins board of KaloBios V Bryan Lawlis joins board of KaloBios

    patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios. ... This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics